Belotecan Versus Topotecan for Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Multicentre, Randomised, Open-Label, Parallel-Group Phase 2b Study of Belotecan Versus Topotecan for Recurrent Ovarian Cancer
Br. J. Cancer 2020 Sep 30;[EPub Ahead of Print], HS Kim, SY Park, CY Park, YT Kim, BJ Kim, YJ Song, BG Kim, YB Kim, CH Cho, JH Kim, YS SongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.